Darren V.S. Green a, Paul D. Leeson b, Robert J. Young
DOI: 10.1016/bs.pmch.2026.10.001
Abstract
The Hit to Lead phase of current drug discovery practice has become a vital element in setting firm foundations for discovery programmes in the quest for new medicines, bridging the gap between screening hits and substantive investment in lead optimisation programmes.
This is not intended to be a comprehensive review of the area, but rather a discussion around observations exploring the options and opportunities in contemporary and future practice. It is framed around the premises of comparing the extent of investment, chances of success, and quality of output – notably in the context of the influence of AI and other changing practices in drug discovery. Key examples are chosen to illustrate the diversity of leads pursued and the levels of investments required to deliver in some areas.